Press Releases

Press Releases

Aug 10, 2020
Announced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373 Secured $2 billion in funding for global coronavirus vaccine program through CEPI, DoD , and OWS Expanded large scale global manufacturing capacity through acquisition and partnering Company to host conference call today at...
Aug 04, 2020
Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across two dose levels (5 and 25 µg) in 131 healthy adults ages 18-59 years NVX-CoV2373 was generally well-tolerated and had a reassuring safety profile The vaccine induced neutralization titers in 100%...
Jul 07, 2020
Funding supports late-stage clinical development, including pivotal Phase 3 clinical trial to support licensure OWS award funds large-scale manufacturing of NVX-CoV2373, including production of 100 million doses starting in late 2020 GAITHERSBURG, Md....
Displaying 1 - 10 of 180